HuidaGene Therapeutics to Attend 2024 BIO International Convention in California for Actively Expanding Global Collaboration

Shanghai and CLINTON (NJ),  May 31^th, 2024 – HuidaGene Therapeutics (“HuidaGene”), a global clinical-stage biotechnology company developing potentially curative genomic medicines, today announced that it will attend the 2024 BIO International Convention to be held from June 3 to 6, 2024 at the San Diego Convention Center in California, USA.

Dr. Alvin Luk, Co-founder and CEO of HuidaGene, and Ms. Xixi Zhu, Senior Director of Business Development of HuidaGene will attend the convention to showcase HuidaGene’s cutting-edge gene-editing technology and innovative gene therapy product pipeline, actively explore global collaboration, and further expand its global footprint. HuidaGene looks forward to conducting in-depth exchanges with multinational corporations and biotechnology companies from around the world on site, and exploring new opportunities for international cooperation and development.

The BIO International Convention, founded in 1993, is the largest, most professional, and influential biotechnology industry event in the world. It brings together leading biopharmaceutical companies, investors, and partners from around the world. Many collaborative activities are held during the conference, providing a platform for promotion and display for enterprises, technology parks, and research and development institutions in various countries. The conference is hosted by the Biotechnology Innovation Organization (BIO) in the United States. BIO is the world's largest biotechnology industry association representing biotechnology companies, academic institutions, and related institutions.

About HuidaGene

HuidaGene Therapeutics utilizes its proprietary CRISPR-based HG-PRECISE^® platform to discover, engineer, and develop potentially curative genomic medicine. The Company is advancing clinical programs of HG004 in RPE65-associated inherited retinal disease (granted both ODD and RPDD), HG202 CRISPR RNA-editing in neovascular age-related macular degeneration, and the preclinical pipeline, including HG204 CRISPR RNA-editing in neurodevelopmental disease of MECP2 duplication syndrome (granted both ODD and RPDD by U.S. FDA and ODD by EMA), HG302 CRISPR DNA-editing for Duchenne muscular dystrophy (granted both ODD and RPDD), and HG303 CRISPR DNA-editing for Amyotrophic Lateral Sclerosis (ALS). The Company’s extensive intellectual property portfolio positions it as a leader in unleashing the full potential of genome medicine. Learn more at huidagene.com or on LinkedIn.